Evidence map›Paper›PMID 36158314›Full record

ArticleLeukemia research reports2022

Acute myeloid leukemia with variant t(8;10;21).

Barbora Bacova, Jiri Sobotka, Petra Kacirkova, Veronika Rivnacova, Ivana Karlova/Zubata, Jan Novak

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia research reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. PredictingiScience · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Barbora BacovaDepartment of Haematology, 3rd Faculty of Medicine, Charles University and Faculty Hospital Kralovske Vinohrady. Srobarova 50, 100 34, Prague 10, Czech Republic.
Jiri SobotkaLaboratory of Medical Genetics, SPADIA LAB a.s., Ostrava, Czech Republic.
Petra KacirkovaCentral laboratories of the Faculty Hospital Kralovske Vinohrady, Czech Republic.
Veronika RivnacovaDepartment of Haematology, 3rd Faculty of Medicine, Charles University and Faculty Hospital Kralovske Vinohrady. Srobarova 50, 100 34, Prague 10, Czech Republic.
Ivana Karlova/ZubataDepartment of Haematology, 3rd Faculty of Medicine, Charles University and Faculty Hospital Kralovske Vinohrady. Srobarova 50, 100 34, Prague 10, Czech Republic.
Jan NovakDepartment of Haematology, 3rd Faculty of Medicine, Charles University and Faculty Hospital Kralovske Vinohrady. Srobarova 50, 100 34, Prague 10, Czech Republic.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The t(8;21)(q22;q22) is one of the most common chromosomal abnormalities in acute myeloid leukemia (AML). Approximately 3-4% of AML cases are associated with additional chromosomal abnormalities. Their impact on the prognosis of the disease remains to be established. Here we report a case of t(8;10;21) AML with mutated c-KIT that shared key morphological features with classical t(8;21) leukemias, including the M2 morphology pattern and CD34, HLA-DR phenotype. The 63-year-old female was treated with two inductioncontaining Daunoribicine and Cytarabine and four cycles of intermediate-dose Cytarabine (1.5 g/m

Indexed as

21)Acute myeloid leukemiaCytogeneticsFluorescence in situ hybridizationt(8

Identifiers

PMID36158314
PMCPMC9489803

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.